This is a product review of the use of encorafenib plus binimetinib in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
This summary presents results of the open-label, phase 3 COLUMBUS trial along with commentary and recommendations from Associate Professor Andrew Haydon, Medical Oncologist at the Alfred Hospital, member of the Victorian Melanoma Service, and Adjunct Senior Lecturer at the Department of Epidemiology and Preventive Medicine, Monash University.
Please login below to download this issue (PDF)